BE2015C046I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C046I2
BE2015C046I2 BE2015C046C BE2015C046C BE2015C046I2 BE 2015C046 I2 BE2015C046 I2 BE 2015C046I2 BE 2015C046 C BE2015C046 C BE 2015C046C BE 2015C046 C BE2015C046 C BE 2015C046C BE 2015C046 I2 BE2015C046 I2 BE 2015C046I2
Authority
BE
Belgium
Application number
BE2015C046C
Other languages
French (fr)
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27482359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C046(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2002/006141 external-priority patent/WO2003000680A1/ja
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BE2015C046I2 publication Critical patent/BE2015C046I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BE2015C046C 2001-06-20 2015-07-16 BE2015C046I2 (en, 2012)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001187105 2001-06-20
JP2001243046 2001-08-09
JP2001311808 2001-10-09
JP2001398708 2001-12-28
PCT/JP2002/002683 WO2003000657A1 (fr) 2001-06-20 2002-03-20 Derives de diamine
PCT/JP2002/006141 WO2003000680A1 (fr) 2001-06-20 2002-06-20 Derives de diamine

Publications (1)

Publication Number Publication Date
BE2015C046I2 true BE2015C046I2 (en, 2012) 2021-07-19

Family

ID=27482359

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C046C BE2015C046I2 (en, 2012) 2001-06-20 2015-07-16

Country Status (12)

Country Link
US (7) US7365205B2 (en, 2012)
EP (1) EP2343290A1 (en, 2012)
AR (1) AR036102A1 (en, 2012)
BE (1) BE2015C046I2 (en, 2012)
CY (2) CY1113054T1 (en, 2012)
FR (1) FR15C0068I2 (en, 2012)
MY (1) MY153231A (en, 2012)
NL (1) NL300760I2 (en, 2012)
PT (1) PT1405852E (en, 2012)
TW (1) TWI298066B (en, 2012)
WO (1) WO2003000657A1 (en, 2012)
ZA (1) ZA200309866B (en, 2012)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2003000657A1 (fr) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
KR100863113B1 (ko) * 2001-06-20 2008-10-13 다이이찌 산쿄 가부시키가이샤 디아민 유도체
MXPA04001272A (es) * 2001-08-09 2004-05-27 Daiichi Seiyaku Co Derivados de diamina.
RU2333203C2 (ru) * 2002-12-25 2008-09-10 Дайити Фармасьютикал Ко., Лтд. Диаминовые производные
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
WO2005032490A2 (en) * 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Cyclic diamines and derivatives as factor xa inhibitors
ES2679744T3 (es) * 2003-11-12 2018-08-30 Daiichi Sankyo Company, Limited Procedimiento para producir derivados de tiazol
US7488747B2 (en) * 2003-12-29 2009-02-10 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
BRPI0512410A (pt) * 2004-06-24 2008-03-04 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
JP2008504280A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
CA2570694A1 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN101001850A (zh) * 2004-06-24 2007-07-18 因塞特公司 酰胺基化合物及其作为药物的应用
EP1773773A4 (en) * 2004-06-24 2009-07-29 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
WO2006020598A2 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
US7499687B2 (en) * 2004-11-09 2009-03-03 Theta Microelectronics, Inc. Wireless transmitter DC offset recalibration
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
US20060122210A1 (en) * 2004-11-18 2006-06-08 Wenqing Yao Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same
HUP0700605A3 (en) * 2005-02-18 2008-02-28 Arpida Ag Novel processes for the preparation of a benzofuran
CN101163700A (zh) * 2005-03-31 2008-04-16 第一三共株式会社 三胺衍生物
CA2957667A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
JPWO2007032371A1 (ja) 2005-09-14 2009-03-19 大日本住友製薬株式会社 摂食調節剤としてのオキシインドール誘導体
JP4510088B2 (ja) * 2005-09-16 2010-07-21 第一三共株式会社 光学活性なジアミン誘導体およびその製造方法
WO2007038138A2 (en) * 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
AR057965A1 (es) * 2005-12-05 2007-12-26 Incyte Corp Compuestos de lactama y metodos de uso de los mismos
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
JP5438975B2 (ja) * 2006-01-06 2014-03-12 サノビオン ファーマシューティカルズ インク テトラロン系モノアミン再取り込み阻害剤
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US20070197530A1 (en) * 2006-01-31 2007-08-23 Yun-Long Li Amido compounds and their use as pharmaceuticals
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EP2013835B1 (en) 2006-03-31 2015-11-04 Sunovion Pharmaceuticals Inc. Preparation of chiral amides and amines
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
JP2009537564A (ja) * 2006-05-17 2009-10-29 インサイト・コーポレイション １１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの複素環阻害剤およびそれを用いる方法
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
EP2044055A4 (en) * 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
WO2008026563A1 (fr) 2006-08-30 2008-03-06 Shionogi & Co., Ltd. Dérivé d'hydrazine amide
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
WO2008089453A2 (en) * 2007-01-18 2008-07-24 Sepracor Inc. Inhibitors of d-amino acid oxidase
CN101652139A (zh) * 2007-03-29 2010-02-17 第一三共株式会社 药物组合物
RU2470011C2 (ru) 2007-05-31 2012-12-20 Сепракор Инк. Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
CL2008001839A1 (es) * 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9776963B2 (en) 2008-11-10 2017-10-03 The Trustees Of The University Of Pennsylvania Small molecule CD4 mimetics and uses thereof
KR20110106840A (ko) * 2008-12-12 2011-09-29 다이이찌 산쿄 가부시키가이샤 광학 활성 카르복실산의 제조 방법
RU2464271C1 (ru) 2008-12-17 2012-10-20 Дайити Санкио Компани, Лимитед Способ получения производного диамина
JPWO2010082531A1 (ja) 2009-01-13 2012-07-05 第一三共株式会社 活性化血液凝固因子阻害剤
EP2407457B1 (en) * 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
WO2010131663A1 (ja) * 2009-05-15 2010-11-18 第一三共株式会社 オキサミド誘導体
BRPI1011804A2 (pt) 2009-06-18 2018-02-27 Daiichi Sankyo Company, Limited composição farmacêutica com solubilidade melhorada
FR2948372B1 (fr) 2009-07-21 2011-07-22 Servier Lab Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011102506A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
EP2540317A4 (en) * 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
JP5749247B2 (ja) 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
CN102791719B (zh) * 2010-03-19 2015-07-29 第一三共株式会社 二胺衍生物的晶体及其制备方法
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
US20140050743A1 (en) 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
EP2730269B1 (en) 2011-07-08 2017-08-23 Daiichi Sankyo Company, Limited Product quality control method
JPWO2013022059A1 (ja) 2011-08-10 2015-03-05 第一三共株式会社 ジアミン誘導体含有医薬組成物
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment
CN102659757B (zh) * 2012-04-24 2013-11-06 南京药石药物研发有限公司 一种合成5-氯-3-噻吩甲醛的中间体及其制备方法
BR112015004190A2 (pt) 2012-09-03 2017-07-04 Daiichi Sankyo Co Ltd composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada
WO2014037900A1 (en) 2012-09-07 2014-03-13 Novartis Ag Indole carboxamide derivatives and uses thereof
EP2922833A1 (en) 2012-11-23 2015-09-30 Daiichi Sankyo Co., Ltd. Process for the preparation of (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
TWI602803B (zh) 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
US20150353577A1 (en) 2013-03-29 2015-12-10 Daiichi Sankyo Company, Limited Method for producing (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one
JP2016529279A (ja) 2013-08-29 2016-09-23 第一三共株式会社 がんの治療又は予防のための剤
EP3125939A1 (en) 2014-03-31 2017-02-08 Daiichi Sankyo Co., Ltd. Use of a factor xa inhibitor for treating and preventing bleeding events and related disorders in patients having sensitivity to vitamin k antagonists used as anticoagulants
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2016025681A1 (en) 2014-08-13 2016-02-18 The Trustees Of The University Of Pennsylvania Inhibitors of hiv-1 entry and methods of use thereof
CN104529729B (zh) * 2014-12-31 2016-03-30 浙江永太科技股份有限公司 一种2-氟-3-氯苯甲醛的制备方法
TWI571460B (zh) 2016-03-14 2017-02-21 中化合成生技股份有限公司 二胺衍生物之製造方法
EP3484893A1 (en) 2016-07-13 2019-05-22 Mylan Laboratories Ltd. Salt of amine-protected (1s,2r,4s)-1,2-amino-n,n-dimethylcyclohexane-4-carboxamide
WO2018069769A1 (en) 2016-10-13 2018-04-19 Daiichi Sankyo Company, Limited Pharmaceutical composition for inhibiting neointima formation of blood vessel
US10301322B2 (en) 2016-12-27 2019-05-28 Apotex Inc. Processes for the preparation of edoxaban and intermediates thereof
SG11201908351TA (en) * 2017-03-10 2019-10-30 Edmond J Lavoie Indole derivatives as efflux pump inhibitors
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
BR112021004656A2 (pt) 2018-09-26 2021-06-01 Jiangsu Hengrui Medicine Co., Ltd. conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
AU2019351427A1 (en) 2018-09-30 2021-04-15 Changzhou Hansoh Pharmaceutical Co., Ltd. Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
CN109942600B (zh) * 2019-04-15 2021-08-20 内蒙古京东药业有限公司 一种依度沙班的制备方法
EP3993792A4 (en) * 2019-07-04 2023-07-26 Glenmark Life Sciences Limited Process for preparation of edoxaban
MX2022000421A (es) 2019-07-10 2022-02-10 Bayer Ag Procedimiento para preparar 2-(fenilimino)-1,3-tiazolidin-4-onas.
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
US20230054458A1 (en) 2019-12-12 2023-02-23 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
CN118787756A (zh) 2020-01-22 2024-10-18 江苏恒瑞医药股份有限公司 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
US20230165969A1 (en) 2020-03-25 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
WO2021190602A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
KR20220160016A (ko) 2020-03-25 2022-12-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-psma 항체-엑사테칸 유사체 접합체 및 그의 의학적 용도
AU2021289927A1 (en) 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
KR20220087933A (ko) 2020-12-18 2022-06-27 엠에프씨 주식회사 디아민 유도체의 제조방법
EP4262760A1 (en) 2020-12-18 2023-10-25 KRKA, d.d., Novo mesto Edoxaban formulation containing no sugar alcohols
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
AU2022386505A1 (en) 2021-11-15 2024-05-23 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
CN116178251A (zh) * 2021-11-26 2023-05-30 上海汇伦医药股份有限公司 一种依度沙班中间体的制备方法
CN116212044A (zh) 2021-12-03 2023-06-06 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
CN114456194B (zh) * 2021-12-14 2023-07-07 浙江九洲药业股份有限公司 甲苯磺酸艾多沙班的中间体及其制备方法
CN115583900A (zh) * 2022-04-29 2023-01-10 张邦成都生物医药科技有限公司 一种高纯度依度沙班中间体的制备方法
WO2023223346A1 (en) 2022-05-16 2023-11-23 Mylan Laboratories Limited An improved process for the preparation of edoxaban intermediate
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
CN115724792A (zh) 2022-11-24 2023-03-03 上海柏狮生物科技有限公司 一种依度沙班关键中间体及其合成方法
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376268A (en) * 1964-02-26 1968-04-02 Monsanto Co Amide-heterocyclic polymers
EP0224566A1 (en) 1985-06-07 1987-06-10 The Upjohn Company Antiarrhythmic use for aminocycloalkylamides
WO1992004017A1 (en) 1990-09-10 1992-03-19 The Upjohn Company Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants
IL100576A (en) 1991-01-18 1995-11-27 Eli Lilley And Company Cephalosporin antibiotics
AU2913292A (en) 1991-11-14 1993-06-15 Bernard Derek Frutin A pressurised container
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
AU6252794A (en) 1993-03-03 1994-09-26 Eli Lilly And Company Balanoids
WO1994021599A1 (en) 1993-03-17 1994-09-29 Meiji Seika Kabushiki Kaisha Novel compound with platelet aggregation inhibitor activity
KR970001164B1 (ko) 1993-06-09 1997-01-29 한국과학기술연구원 세팔로스포린계 항생제 및 그의 제조방법
DE69426602T2 (de) 1993-10-19 2001-08-30 Sumitomo Pharmaceuticals Co., Ltd. 2,3-diaminopropionsäurederivate
TW270114B (en, 2012) 1993-10-22 1996-02-11 Hoffmann La Roche
US5525042A (en) 1993-11-08 1996-06-11 Clearline Systems, Inc. Liquid pump with compressed gas motive fluid
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
WO1995032965A1 (fr) 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Derive de l'oxadiazole et composition medicinale a base de ce dernier
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
ES2194986T3 (es) 1995-04-07 2003-12-01 Schering Corp Compuestos de carbonil-piperazinilo y piperidinilo que inhiben la farnesil-protein-transferasa.
ZA963391B (en) 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5726126A (en) 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
DE19536783A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
US5852045A (en) 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
ATE269312T1 (de) 1996-04-17 2004-07-15 Bristol Myers Squibb Pharma Co N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
DE69718177T2 (de) 1996-08-14 2003-10-23 Astrazeneca Ab, Soedertaelje Substituierte pyrimidinderivate und ihre pharmazeutische anwendung
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
WO1998035956A1 (en) 1997-02-13 1998-08-20 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
IT1291823B1 (it) 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
EP0986551B1 (en) 1997-05-30 2006-08-02 Takeda Pharmaceutical Company Limited Sulfonamide derivatives, their production and use
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
JP2002512633A (ja) 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー 抗血栓剤
CA2295153A1 (en) 1997-06-26 1999-01-07 Gerald Floyd Smith Antithrombotic agents
EP1007037A4 (en) 1997-06-26 2004-10-06 Lilly Co Eli ANTITHROMBOTIC AGENTS
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE69833036T2 (de) 1997-09-30 2006-06-22 Daiichi Pharmaceutical Co., Ltd. Sulfonylderivate
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
US6130349A (en) 1997-12-19 2000-10-10 The Board Of Trustees Of The Leland Stanford Junior University Catalytic compositions and methods for asymmetric allylic alkylation
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
EP0937723A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DE19814801A1 (de) 1998-04-02 1999-10-07 Basf Ag Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen
GB9807104D0 (en) 1998-04-02 1998-06-03 Chirotech Technology Ltd The preparation of phosphine ligands
KR20010042868A (ko) 1998-04-21 2001-05-25 블레어 큐. 퍼거슨 항암제 및 증식 억제제로서의5-아미노인데노[1,2-ｃ]피라졸-4-온
GB9809350D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Novel salt
TR200003200T2 (tr) 1998-05-02 2001-02-21 Astrazeneca Ab Faktör XA'yı önleyen heterosiklik türevler.
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
AU4631499A (en) 1998-06-30 2000-01-17 Chirotech Technology Limited The preparation of arylphosphines
JP2000086659A (ja) 1998-07-14 2000-03-28 Takeda Chem Ind Ltd オクタヒドロピリド［１，２―ａ］ピラジン誘導体
TW434207B (en) 1998-07-24 2001-05-16 Everlight Chem Ind Corp Chiral ligand and method for preparing cyanohydrins from aldehydes
US6303625B1 (en) 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
EP1104754A1 (en) * 1998-08-11 2001-06-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
WO2000039111A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Antithrombotic amides
ES2196917T3 (es) 1998-12-23 2003-12-16 Lilly Co Eli Amidas heteroaromaticas como inhibidores del factor xa`.
JP2002533454A (ja) 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー 芳香族アミド類
AU2364000A (en) 1998-12-24 2000-07-31 Eli Lilly And Company Heterocyclic amides as inhibitors of factor xa
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
AU2241400A (en) 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
JP4390024B2 (ja) 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
GB9909592D0 (en) * 1999-04-26 1999-06-23 Chirotech Technology Ltd Process for the preparation of calanolide precursors
WO2000071515A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc INHIBITORS OF FACTOR Xa
ATE303988T1 (de) 1999-06-14 2005-09-15 Lilly Co Eli Inhibitoren von serin proteasen
CA2374553A1 (fr) * 1999-06-15 2000-12-21 Rhodia Chimie Sulfonylamides et carboxamides et leur application en catalyse asymetrique
GB9914342D0 (en) 1999-06-19 1999-08-18 Zeneca Ltd Compound
JP2001011071A (ja) 1999-06-25 2001-01-16 Mochida Pharmaceut Co Ltd アミノアルキルスルホンアミド誘導体
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
GB9917344D0 (en) 1999-07-24 1999-09-22 Zeneca Ltd Novel salt
JP2003509409A (ja) 1999-09-13 2003-03-11 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド アザシクロアルカノンセリンプロテアーゼ阻害剤
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
KR100760434B1 (ko) 1999-09-17 2007-10-04 밀레니엄 파머슈티컬스 인코퍼레이티드 벤즈아미드 및 관련된 Ｘａ 인자의 억제제
EP1235807A1 (en) 1999-11-24 2002-09-04 Millennium Pharmaceuticals, Inc. B-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
WO2001064643A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US6586418B2 (en) 2000-06-29 2003-07-01 Bristol-Myers Squibb Company Thrombin or factor Xa inhibitors
AU2001294824A1 (en) 2000-09-29 2002-04-08 Millennium Pharmaceuticals, Inc. Piperazine based inhibitors of factor xa
EP1322643A1 (en) 2000-09-29 2003-07-02 Millennium Pharmaceuticals, Inc. Piperazin-2-one amides as inhibitors of factor xa
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
JP3903920B2 (ja) 2000-11-22 2007-04-11 アステラス製薬株式会社 置換ベンゼン誘導体又はその塩
WO2002060859A2 (en) 2000-12-20 2002-08-08 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP1373194B1 (en) 2001-03-30 2007-08-01 Millennium Pharmaceuticals, Inc. BENZAMIDE INHIBITORS OF FACTOR Xa
KR100863113B1 (ko) * 2001-06-20 2008-10-13 다이이찌 산쿄 가부시키가이샤 디아민 유도체
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
MXPA04001272A (es) 2001-08-09 2004-05-27 Daiichi Seiyaku Co Derivados de diamina.
CA2726702A1 (en) 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
US20070129371A1 (en) * 2002-12-24 2007-06-07 Daiichi Pharmaceutical Co., Ltd. Novel ethylenediamine derivatives
RU2333203C2 (ru) * 2002-12-25 2008-09-10 Дайити Фармасьютикал Ко., Лтд. Диаминовые производные

Also Published As

Publication number Publication date
FR15C0068I2 (fr) 2016-04-22
NL300760I2 (en) 2017-07-20
US20080015215A1 (en) 2008-01-17
HK1092461A1 (en) 2007-02-09
US20050119486A1 (en) 2005-06-02
CY2015034I1 (el) 2016-04-13
US20090270446A1 (en) 2009-10-29
ZA200309866B (en) 2005-03-30
TWI298066B (en) 2008-06-21
AR036102A1 (es) 2004-08-11
US7342014B2 (en) 2008-03-11
MY153231A (en) 2015-01-29
CY2015034I2 (el) 2016-04-13
US20050020645A1 (en) 2005-01-27
US20110077266A1 (en) 2011-03-31
WO2003000657A1 (fr) 2003-01-03
EP2343290A1 (en) 2011-07-13
FR15C0068I1 (en, 2012) 2015-12-04
US20110312990A1 (en) 2011-12-22
PT1405852E (pt) 2012-10-30
US7365205B2 (en) 2008-04-29
US20100093785A1 (en) 2010-04-15
CY1113054T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
BE2015C046I2 (en, 2012)
BE2014C036I2 (en, 2012)
BE2014C004I2 (en, 2012)
BE2012C050I2 (en, 2012)
BE2012C020I2 (en, 2012)
BE2011C034I2 (en, 2012)
BE2007C047I2 (en, 2012)
AU2002307149A8 (en, 2012)
JP2002204281A5 (en, 2012)
JP2001318627A5 (en, 2012)
BRPI0209186B1 (en, 2012)
BRPI0204884A2 (en, 2012)
JP2002195166A5 (en, 2012)
IN2003CH01280A (en, 2012)
JP2002063764A5 (en, 2012)
JP2002028992A5 (en, 2012)
JP2002144115A5 (en, 2012)
BRPI0210463A2 (en, 2012)
JP2002118458A5 (en, 2012)
AU2000280389A8 (en, 2012)
JP2002069739A5 (en, 2012)
JP2001321045A5 (en, 2012)
BRMU8103221U (en, 2012)
JP2001293196A5 (en, 2012)
AU2001244682A1 (en, 2012)